{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:51:31Z","timestamp":1761947491629},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00432-008-0419-x","type":"journal-article","created":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T12:40:46Z","timestamp":1211805646000},"page":"1303-1310","source":"Crossref","is-referenced-by-count":10,"title":["Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease"],"prefix":"10.1007","volume":"134","author":[{"given":"Kyriaki","family":"Mystakidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Stathopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efi","family":"Parpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilios","family":"Kouloulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Kouskouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambros","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191\u20131200. doi:10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","journal-title":"Cancer"},{"key":"419_CR2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","volume":"45","author":"A Berruti","year":"1999","unstructured":"Berruti A, Dogliotti L, Gorzegno G et al (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45:1240\u20131247","journal-title":"Clin Chem"},{"key":"419_CR3","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, for the MF 4265 Study Group et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405. doi: 10.1093\/annonc\/mdg367","journal-title":"Ann Oncol"},{"key":"419_CR4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133\u20131137. doi: 10.1038\/sj.bjc.6601663","journal-title":"Br J Cancer"},{"key":"419_CR5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdm119","volume":"18","author":"JJ Body","year":"2007","unstructured":"Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstrom B (2007) Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 18:1165\u20131171. doi: 10.1093\/annonc\/mdm119","journal-title":"Ann Oncol"},{"key":"419_CR6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031\u20132037. doi: 10.1038\/sj.bjc.6601437","journal-title":"Br J Cancer"},{"key":"419_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumours. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"419_CR8","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676\u20131679. doi: 10.1056\/NEJM200310233491721","journal-title":"N Engl J Med"},{"key":"419_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176. doi: 10.1053\/ctrv.2000.0210","journal-title":"Cancer Treat Rev"},{"key":"419_CR10","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cncr.10522","volume":"94","author":"RE Coleman","year":"2002","unstructured":"Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521\u20132533. doi: 10.1002\/cncr.10522","journal-title":"Cancer"},{"issue":"20 suppl","key":"419_CR11","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 suppl):6243s\u20136249s. doi: 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"key":"419_CR12","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925\u20134935. doi: 10.1200\/JCO.2005.06.091","journal-title":"J Clin Oncol"},{"key":"419_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CBC.2000.n.003","volume":"1","author":"IJ Diel","year":"2000","unstructured":"Diel IJ, Solomayer EF, Bastert G (2000) Treatment of metastatic bone disease in breast cancer: bisphosphonated. Clin Breast Cancer 1:43\u201351","journal-title":"Clin Breast Cancer"},{"key":"419_CR14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","volume":"89","author":"SM Domchek","year":"2000","unstructured":"Domchek SM, Younger J, Finkelstein DM, Seiden MV (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363\u2013368. doi:10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","journal-title":"Cancer"},{"key":"419_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/ctrv.2000.0213","volume":"27","author":"P Garnero","year":"2001","unstructured":"Garnero P (2001) Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187\u2013192. doi: 10.1053\/ctrv.2000.0213","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 5","key":"419_CR16","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","volume":"1","author":"A Heidenreich","year":"2003","unstructured":"Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl 5):S270","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"419_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.10-90001-14","volume":"10","author":"GH Jackson","year":"2005","unstructured":"Jackson GH (2005) Renal safety of ibandronate. Oncologist 10(Suppl 1):14\u201318. doi: 10.1634\/theoncologist.10-90001-14","journal-title":"Oncologist"},{"key":"419_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejcsup.2004.01.003","volume":"2","author":"B Leyland-Jones","year":"2004","unstructured":"Leyland-Jones B (2004) Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. Eur J Cancer suppl 2:9\u201312","journal-title":"Eur J Cancer suppl"},{"key":"419_CR19","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","volume":"34","author":"A Lipton","year":"1998","unstructured":"Lipton A, Demers L, Curley E et al (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021\u20132026. doi: 10.1016\/S0959-8049(98)00277-9","journal-title":"Eur J Cancer"},{"issue":"Suppl 16 S","key":"419_CR20","first-page":"115","volume":"23","author":"A Lipton","year":"2005","unstructured":"Lipton A, Hei Y, Coleman R, Major P, Cook R (2005) Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. J Clin Oncol 23(Suppl 16 S):115 Abstract 532","journal-title":"J Clin Oncol"},{"key":"419_CR21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","volume":"39","author":"GS Markowitz","year":"2002","unstructured":"Markowitz GS, Fine PL, D\u2019agati VD (2002) Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39:1118\u20131122. doi: 10.1053\/ajkd.2002.32797","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"419_CR22","first-page":"iii50","volume":"15","author":"C McPartland","year":"2004","unstructured":"McPartland C, Grosjean L (2004) Treatment of painful bone metastases in Europe and Canada: the role of bisphosphonates. Ann Oncol 15(Suppl 3):iii50 abstract","journal-title":"Ann Oncol"},{"key":"419_CR23","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD, Sakalov\u00e1 A, Fontana A et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353\u20132359. doi: 10.1200\/JCO.2002.02.032","journal-title":"J Clin Oncol"},{"key":"419_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ctrv.2005.03.005","volume":"31","author":"K Mystakidou","year":"2005","unstructured":"Mystakidou K, Katsouda E, Stathopoulou E, Vlahos L (2005) Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 31:303\u2013311. doi: 10.1016\/j.ctrv.2005.03.005","journal-title":"Cancer Treat Rev"},{"key":"419_CR25","first-page":"396","volume":"11","author":"C Ohlmann","year":"2003","unstructured":"Ohlmann C, Heidenreich A (2003) Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 11:396 Abstract A\u201338","journal-title":"Support Care Cancer"},{"key":"419_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","volume":"26","author":"M Pecherstorfer","year":"2006","unstructured":"Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstr\u00f6m B (2006) Long-term safety of intravenous ibandronic acid for up to 4\u00a0years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26:315\u2013322. doi: 10.2165\/00044011-200626060-00002","journal-title":"Clin Drug Investig"},{"key":"419_CR27","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664. doi: 10.1056\/NEJMra030831","journal-title":"N Engl J Med"},{"key":"419_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","volume":"24","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M, Tsota I, Kardamakis D (2007) A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24:169\u2013178. doi: 10.1007\/s10585-007-9066-x","journal-title":"Clin Exp Metastasis"},{"key":"419_CR29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1464-410X.2003.04362.x","volume":"92","author":"J Yahara","year":"2003","unstructured":"Yahara J, Noguchi M, Noda S (2003) Quantitative evaluation of bone metastasis in patients with advanced prostate cancer during systemic treatment. BJU Int 92:379\u2013384. doi: 10.1046\/j.1464-410X.2003.04362.x","journal-title":"BJU Int"},{"key":"419_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2003.10.003","volume":"27","author":"V Yau","year":"2004","unstructured":"Yau V, Chow E, Davis L, Holden L, Schueller T, Danjoux C (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 27:1\u20133. doi: D:10.1016\/j.jpainsymman.2003.10.003","journal-title":"J Pain Symptom Manage"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0419-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-008-0419-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-008-0419-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:28:57Z","timestamp":1588721337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-008-0419-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s00432-008-0419-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}